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Case Report: Covid-19 Associated Guillain-Barre Syndrome
Matthew Aharonov DO, Neelesh Parikh DO, James Espinosa MD, Alan Lucerna DO
Emergency Medicine Residency and Department of Emergency Medicine, Rowan University, SOM

Abstract:

Discussion continued:

We report a case of a 72-year-old female who presented
to the emergency department with a complaint of
generalized weakness. The patient was found to have
ascending muscle weakness and subsequently diagnosed
with Covid-19 related Guillain-Barre Syndrome. Our
patient was negative for Campylobacter jejuni. It is
noteworthy that the patient did not have fever,
respiratory symptoms or loss of the sensation of taste.

More rapid onset and progression of symptoms is associated
with poorer outcomes.
There are a few reported world-wide cases of GBS following
Covid-19 infection. [Rajdev, 2019]
A review of 37 cases of Covid-19 associated GBS found that the
mean time to presentation from the onset was 11 days. When
assessed, albuminocytologic dissociation was found in 76% of
cases. Serum anti-ganglioside antibodies were absent in the
majority of cases where assessed. [Caress, 2020]
GBS is a clinical diagnosis, based on physical exam and history.
While lumbar puncture results such as cytology can support
the diagnosis, this confirmation is unnecessary to establish
diagnosis. The review by Caress of Covid-19 related GBS found
paresthesias in 68% of cases, limb weakness in 68% of cases
and cranial nerve symptoms in 35% of cases. [Caress, 2020]]
Our patient was afebrile and had not preceding respiratory
symptoms. Patients have also been reported with Covid-19
associated GBS in which there were no preceding respiratory
symptoms and no fever. [Scheidl, 2020]. The patient did not
have loss of taste. Patients with Covid-19 GBS have been
reported in which there is no loss of taste. [Rana, 2020
Early detection of GBS may decrease or reverse disease
progression. Initiation of intravenous immunoglobulin (IVIG)
therapy is an option. Plasmapheresis is another therapeutic
option for GBS.

Case Presentation:
A 72-year-old female presented to the Emergency
Department (ED) for the evaluation of bilateral lower
extremity weakness. Her past medical history included
sarcoidosis, chronic low back pain, paroxysmal atrial
fibrillation, hypertension, a non-toxic multinodular goiter
and thyrotoxicosis An acute gastrointestinal stool panel
taken during a recent hospitalization for diverticulitis was
negative for Campylobacter jejuni.
She denied subjective fever or chills. She denied
headache, dizziness, myalgias, change or loss in sense of
taste, cough or sore throat. Her vital signs were within
normal limits. She had absent patellar reflexes bilaterally,
with a normal Achilles reflex. Muscle strength in bilateral
lower extremities was 1/5. Sensation in the lower
extremities was normal.
On laboratory testing, she was noted to have leukopenia.
A PCR test for Covid-19 was positive. MRI of the cervical,
thoracic and lumbar spine revealed no abnormalities that
could be associated with patient’s presentation. Lumbar
puncture was unobtainable secondary to chronic
anticoagulation. A diagnosis of Guillain-Barre Syndrome
(GBS) was made. The patient was treated with a 5 day
course of IVIG was initiated in the ED. The patient’s
motor strength improved significantly by the time of
discharge and at the time of out-patient follow up was
able to walk unassisted with some persistent thigh
weakness.
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Discussion:
Covid-19 is a novel coronavirus infection. The most commonly
associated symptoms are fever, myalgias and respiratory and
gastrointestinal symptoms. Neurological diagnoses have been
reported including stroke, headache and dizziness.
GBS is an acute, generalized polyradiculoneuropathy that has
been associated with a wide-variety of pathogens, including
Campylobacter jejuni, EB virus, influenza, CMV and the Zika virus.
It has been seen after influenza vaccinations. [Caress, 2020]
GBS is felt to be caused by an autoimmune response that triggers
a cross-reaction to ganglioside components of peripheral nerves.
[Scheidl, 2020]
Most patients with GBS report neurological symptoms within 2
days to 12 weeks of a diarrheal illness. Paresthesias may precede
motor symptoms. Symptom progression is typically symmetric,
starting distally. Lower back pain is a common complaint. Gait
abnormalities, difficulty standing up are common complaints.
Deep-tendon reflexes are depressed or absent in the majority of
patients. Respiratory depression and cranial neuropathy often
occur later. Symptoms may begin in as little as 12 hours but
progression past 28 days is very rare.

Conclusions:
Novel pathogens carry with them new pathologies that
require elucidation. SARS-CoV-2 exemplifies this idea, and
has been implicated in a variety of unusual pathologies not
commonly associated with viral infection. Several cases of
Guillain-Barre Syndrome associated with Covid-19 have
been reported. Our case is unique in that the patient did not
present with any overt signs of Covid-19 infection, such as
respiratory symptoms. Covid-19 should be considered in any
patient with acute ascending symmetrical weakness,
paresthesias, and historical features of GBS; likewise the
reverse is true, any patient with Covid-19 should receive a
neurological exam and historical questions relating to motor
strength
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